Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MSH6 | ISIN: CH0029850754 | Ticker-Symbol: APE
Frankfurt
05.06.25 | 09:10
0,058 Euro
-9,45 % -0,006
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ADDEX THERAPEUTICS SA Chart 1 Jahr
5-Tage-Chart
ADDEX THERAPEUTICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,0600,06310:40
GlobeNewswire (Europe)
181 Leser
Artikel bewerten:
(1)

Addex Therapeutics: Addex Convenes Annual General Meeting 2025

Geneva, Switzerland, June 3, 2025 -Addex Therapeutics(SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will take place on Tuesday June 24, 2025, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am).

Agenda

1. Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the business year 2024


2. Consultative vote on the Compensation Report for the business year 2024


3. Appropriation of the results


4. Discharge of the members of the Board of Directors and of the Executive Management


5. Re-elections of the members of the Board of Directors and re-election of the Chairman of the Board of Directors


5.1. Re-election of Vincent Lawton as member and Chairman of the Board of Directors
5.2. Re-election of Raymond Hill as member of the Board of Directors
5.3. Re-election of Timothy Dyer as member of the Board of Directors
5.4. Re-election of Roger Mills as member of the Board of Directors
5.5. Re-election of Jake Nunn as member of the Board of Directors
5.6. Re-election of Isaac Manke as member of the Board of Directors


6. Re-elections of the members of the Compensation Committee


6.1. Re-election of Vincent Lawton as member of the Compensation Committee
6.2. Re-election of Raymond Hill as member of the Compensation Committee


7. Re-election of the Auditors


8. Re-election of the Independent Voting Rights Representative


9. Approval of the compensation of the members of the Board of Directors and of the Executive Management


9.1. Compensation of the members of the Board of Directors
9.2. Compensation of the members of the Executive Management


10. Miscellaneous


The full invitation to the AGM 2025 may be found in the General Meetings section of the Company's website here.

About Addex:

Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant

Contacts:

Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
PR@addextherapeutics.com (mailto:PR@addextherapeutics.com)
Mike Sinclair
Partner, Halsin Partners
+44 (0)7968 022075
msinclair@halsin.com (mailto:msinclair@halsin.com)

Addex Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.


© 2025 GlobeNewswire (Europe)
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.